Document is current
Any future updates will be listed below
-
Authors
Baeza-Centurión, Pablo https://orcid.org/0000-0002-8141-8075
Miñana, Belén https://orcid.org/0000-0001-7676-5788
Faure, Andre J. https://orcid.org/0000-0002-4471-5994
Thompson, Mike
Bonnal, Sophie https://orcid.org/0000-0001-6096-3042
Quarantani, Gioia https://orcid.org/0009-0008-2794-2678
Clarke, Joseph https://orcid.org/0009-0002-2466-9932
Lehner, Ben https://orcid.org/0000-0002-8817-1124
Valcárcel, Juan https://orcid.org/0000-0001-5398-3571
- License Information
-
More Information
Article History
Received: 23 April 2024
Accepted: 4 August 2025
First Online: 30 August 2025
Competing interests
: CRG has filed a patent (European Priority Application 24382126.0) for the use of deep indel mutagenesis as a method to identify and predict the effects of antisense oligonucleotides. P.B.-C., B.M., B.L. and J.V. are listed as co-inventors. J.V. is a member of the Scientific Advisory Boards of Remix Therapeutics, Stoke Therapeutics and IntronX. The remaining authors declare no competing interests.
